Emergent BioSolutions (NYSE:EBS) Trading 7.2% Higher – Should You Buy?

Emergent BioSolutions Inc. (NYSE:EBS) shares were up 7.2% during trading on Wednesday . The stock traded as high as $10.95 and last traded at $10.96. Approximately 908,581 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 972,512 shares. The stock had previously closed at $10.22.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on EBS shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Performance

The company has a market cap of $587.53 million, a PE ratio of -2.64 and a beta of 1.60. The business’s 50-day moving average is $9.27 and its 200 day moving average is $9.24. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Emergent BioSolutions (NYSE:EBS) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. During the same quarter last year, the company earned ($1.44) EPS. On average, equities research analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Emergent BioSolutions

Hedge funds have recently modified their holdings of the company. American Century Companies Inc. boosted its stake in shares of Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions during the second quarter worth about $93,000. Hsbc Holdings PLC boosted its stake in Emergent BioSolutions by 36.1% during the second quarter. Hsbc Holdings PLC now owns 87,679 shares of the biopharmaceutical company’s stock worth $614,000 after acquiring an additional 23,250 shares in the last quarter. XTX Topco Ltd boosted its stake in Emergent BioSolutions by 218.0% during the second quarter. XTX Topco Ltd now owns 62,764 shares of the biopharmaceutical company’s stock worth $428,000 after acquiring an additional 43,028 shares in the last quarter. Finally, Morse Asset Management Inc bought a new stake in Emergent BioSolutions during the second quarter worth about $97,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.